|A new drug can reduce heart failure deaths by 20%, scientists in Scotland claim. (Fotolia) |
A new drug can reduce heart failure deaths by 20%, scientists in Scotland claim.
LCZ696 is designed for patients with chronic heart failure, a condition in which the heart doesn't pump blood efficiently.
“We have what we believe is a much more effective replacement for one of the gold standard drugs for the treatment of heart failure,” Prof. John McMurray, a principal researcher from the University of Glasgow, told The Independent. “This is a major advance in the treatment of this terrible problem.”
The study was designed to measure whether LCZ696 could increase survival by at least 15%, a level that might encourage cardiologists to make it the standard treatment.
The drug surpassed that threshold when measured by deaths caused by cardiovascular issues or those occurring from any cause.
Patient deaths from any cause in the group taking LCZ696 were 16% lower than in the group taking enalapril, according to the results.
The group taking LCZ696 had a 21% lower risk of hospitalization.
It is not yet available to the public since the manufacturers, Novartis International, must gain the approval of the Medicines and Healthcare Products Regulatory Agency to sell the drug.
The study was published online in the New England Journal of Medicine.
Did you find what you were looking for on our website? Please let us know.